1. Home
  2. APRE vs CWD Comparison

APRE vs CWD Comparison

Compare APRE & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.24

Market Cap

5.7M

Sector

Health Care

ML Signal

HOLD

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

SELL

Current Price

$0.35

Market Cap

4.6M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
APRE
CWD
Founded
2006
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.7M
4.6M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
APRE
CWD
Price
$0.24
$0.35
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
★ $3.30
N/A
AVG Volume (30 Days)
★ 133.5K
91.4K
Earning Date
11-04-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 21.22
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $20,097,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.16
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.39
$0.33
52 Week High
$1.49
$2.57

Technical Indicators

Market Signals
Indicator
APRE
CWD
Relative Strength Index (RSI) 26.17 35.56
Support Level N/A N/A
Resistance Level $0.81 $0.50
Average True Range (ATR) 0.06 0.04
MACD -0.01 -0.00
Stochastic Oscillator 8.91 21.58

Price Performance

Historical Comparison
APRE
CWD

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm investing across real and digital assets. It sponsors and manages private real estate investment funds and maintains a digital asset treasury approach focused on blockchain infrastructure assets. The company's activities are supported by transaction and advisory services, including development and construction management, acquisition and disposition services, brokerage, and fund formation services. The company operates through one reportable segment. It generates the majority of its revenue in the form of asset management fee revenues and performance allocations.

Share on Social Networks: